


AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of claims:


1. (Currently Amended) A composition for cancer treatment comprising a pharmaceutically acceptable carrier and a compound represented by formula 1 or a pharmaceutically acceptable carrier and a pharmaceutically acceptable salt thereof of the compound represented by formula 1, wherein the cancer is selected from the group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:



wherein, R¹ is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

2.-3. (Cancelled)


4. (Currently Amended) A composition for the enhancement of radiosensitizing effect comprising a pharmaceutically acceptable carrier and a compound represented by formula 1 or a pharmaceutically acceptable carrier and a pharmaceutically acceptable salt of the compound represented by the formula 1:



wherein, R¹ is propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

5.-6. (Cancelled)

7. (Withdrawn) A method for treating a cancer comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt thereof, wherein the cancer is selected from a group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer:




wherein, R¹ is hydrogen or a substituted or unsubstituted C₁-C₂₀ alkylcarbonyl group.

8. (Withdrawn) The method according to claim 7, wherein R¹ is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

9. (Withdrawn) The method according to claim 7, wherein R^1 is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.

10. (Withdrawn) A method for enhancing radiosensitizing effect effect comprising administering to a human in need of treatment a therapeutically effective amount of a compound represented by formula 1 or a pharmaceutically acceptable salt:



wherein, R^1 is hydrogen or a substituted or unsubstituted C_1 - C_{20} alkylcarbonyl group.

11. (Withdrawn) The method according to claim 10, wherein R^1 is hydrogen, ethanoyl group, propanoyl group, butanoyl group, pentanoyl group, hexanoyl group, heptanoyl group, octanoyl group, nonanoyl group, decanoyl group, undecanoyl group, or dodecanoyl group.

12. (Withdrawn) The method according to claim 10, wherein R^1 is hydrogen, butanoyl group, hexanoyl group, or octanoyl group.

13. (New) A composition for cancer treatment comprising:

a pharmaceutically acceptable carrier and a compound obtained from an acylation of an amino group on phytosphingosine or a pharmaceutically acceptable carrier and a compound obtained from an acylation of an amino group on phytosphingosine derivative wherein the cancer is selected from the group consisting of lung cancer, uterine cancer, breast cancer and blood cell cancer; and wherein the phytosphingosine derivative is one having an alkylcarbonyl group that is selected from the group consisting of a propanoyl group, a butanoyl group, a pentanoyl group, a hexanoyl group, a heptanoyl group, an octanoyl group, a nonanoyl group, a decanoyl group, an undecanoyl group, or a dodecanoyl group.